{"id":"W4381838960","doi":"10.1182/bloodadvances.2023010254","title":"Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Seagen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Nivolumab; Neutropenia; Oncology; Adverse effect; Transplantation; Clinical endpoint; Confidence interval; Lymphoma; Surgery; Chemotherapy; CD30; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001558014,0.0002927821,0.0005376952,0.0001291027,0.0001940308,0.00002984044,0.0001243079,0.00007068409,0.00003516985],"category_scores_gemma":[0.00006187079,0.0002153483,0.0001789595,0.0003925204,0.00006645191,0.0001521229,0.0000685804,0.00005017903,0.0001299731],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000920037,"about_ca_system_score_gemma":0.0002639712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001619528,"about_ca_topic_score_gemma":0.00006086075,"domain_scores_codex":[0.9981134,0.00002408189,0.0002838629,0.0004938202,0.0004252513,0.0006595635],"domain_scores_gemma":[0.9989607,0.0002462181,0.0001348091,0.0003277892,0.0001262797,0.0002041832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02208675,0.0524713,0.7516983,0.00417045,0.002388713,0.002876064,0.001881707,0.00002069706,0.003241684,0.003589029,0.03268051,0.1228948],"study_design_scores_gemma":[0.4840712,0.01584226,0.3254312,0.0009621298,0.002832151,0.000274413,0.001616177,0.0001960374,0.03174592,0.0005465681,0.1353872,0.001094769],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899323,0.002746178,0.00007355433,0.0006964285,0.0004337627,0.001267005,0.0001721684,0.0003624701,0.004316124],"genre_scores_gemma":[0.9905146,0.0005748619,0.003409655,0.000371643,0.0002584829,0.0007025612,0.0005333752,0.00006908751,0.003565677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4619845,"threshold_uncertainty_score":0.8781651,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0092442261172573,"score_gpt":0.241202458622175,"score_spread":0.2319582325049176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}